Staging, ctDNA, and the Art of Personalizing Metastatic Breast Cancer Therapy: Hayley Knollman, MD

Why It Matters

Personalized genomic testing can steer more effective treatment choices, potentially extending survival and improving quality of life for patients with metastatic ER‑positive breast cancer.

Key Takeaways

• Standard staging still dominates initial breast‑cancer assessment
• HER2‑low/ultra‑low impact emerges in metastatic setting
• ctDNA is accessible but lacks consensus testing guidelines
• Knollman repeats genomic testing at diagnosis and progression

Pulse Analysis

The landscape of metastatic estrogen‑receptor‑positive breast cancer is shifting from a one‑size‑fits‑all model to a nuanced, genomics‑driven approach. While traditional staging—blood panels, imaging, and tissue biopsies—remains the foundation, clinicians are now forced to consider HER2‑low and HER2‑ultra‑low subtypes that only become actionable once the disease advances. Early comprehensive profiling therefore sets the stage for later therapeutic decisions, ensuring that emerging biomarkers are not missed when they matter most.

Circulating tumor DNA (ctDNA) and next‑generation sequencing panels have entered routine oncology practice, yet their optimal deployment remains ambiguous. Dr. Knollman advocates a pragmatic schedule: perform a full genomic assay at the moment metastatic disease is confirmed, repeat a tissue‑based test at any documented progression, and intersperse ctDNA snapshots to capture evolving resistance mechanisms. This strategy balances the cost and logistical burden of testing with the clinical need to stay ahead of tumor evolution, a critical factor as patients often live many years with metastatic disease.

Therapeutic sequencing now hinges on molecular insights. ESR1 mutations signal resistance to aromatase inhibitors, while PIK3CA alterations open the door to PI3K‑targeted agents. First‑line regimens—typically an aromatase inhibitor plus a CDK4/6 inhibitor—remain standardized, but subsequent lines require a tailored blend of endocrine therapy, targeted agents, and chemotherapy based on mutation status, prior response duration, and disease tempo. As the arsenal expands, oncologists must blend data‑driven precision with clinical judgment, turning the management of metastatic breast cancer into a sophisticated art form. Continued research and clearer guidelines will be essential to translate these genomic tools into consistent, outcome‑improving practice.